Literature DB >> 21917975

Differential reactivity of germ line allelic variants of a broadly neutralizing HIV-1 antibody to a gp41 fusion intermediate conformation.

S Munir Alam1, Hua-Xin Liao, S Moses Dennison, Frederick Jaeger, Robert Parks, Kara Anasti, Andrew Foulger, Michele Donathan, Judith Lucas, Laurent Verkoczy, Nathan Nicely, Georgia D Tomaras, Garnett Kelsoe, Bing Chen, Thomas B Kepler, Barton F Haynes.   

Abstract

Genetic factors, as well as antigenic stimuli, can influence antibody repertoire formation. Moreover, the affinity of antigen for unmutated naïve B cell receptors determines the threshold for activation of germinal center antibody responses. The gp41 2F5 broadly neutralizing antibody (bNAb) uses the V(H)2-5 gene, which has 10 distinct alleles that use either a heavy-chain complementarity-determining region 2 (HCDR2) aspartic acid (D(H54)) or an HCDR2 asparagine (N(H54)) residue. The 2F5 HCDR2 D(H54) residue has been shown to form a salt bridge with gp41 (665)K; the V(H)2-5 germ line allele variant containing N(H54) cannot do so and thus should bind less avidly to gp41. Thus, the induction of 2F5 bNAb is dependent on both genetic and structural factors that could affect antigen affinity of unmutated naïve B cell receptors. Here, we studied allelic variants of the V(H)2-5 inferred germ line forms of the HIV-1 gp41 bNAb 2F5 for their antigen binding affinities to gp41 linear peptide and conformational protein antigens. Both V(H)2-5 2F5 inferred germ line variants bound to gp41 peptides and protein, including the fusion intermediate protein mimic, although more weakly than the mature 2F5 antibody. As predicted, the affinity of the N(H54) variant for fusion-intermediate conformation was an order of magnitude lower than that of the D(H54) V(H)2-5 germ line antibody, demonstrating that allelic variants of 2F5 germ line antibodies differentially bind to gp41. Thus, these data demonstrate a genetically determined trait that may affect host responses to HIV-1 envelope epitopes recognized by broadly neutralizing antibodies and has implications for unmutated ancestor-based immunogen design.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21917975      PMCID: PMC3209283          DOI: 10.1128/JVI.05680-11

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  48 in total

1.  VH4.21 expression in the normal human B-cell repertoire.

Authors:  D F Friedman; P Kraj; L E Silberstein
Journal:  Ann N Y Acad Sci       Date:  1995-09-29       Impact factor: 5.691

Review 2.  A complete map of the human immunoglobulin VH locus.

Authors:  I M Tomlinson; G P Cook; G Walter; N P Carter; H Riethman; L Buluwela; T H Rabbitts; G Winter
Journal:  Ann N Y Acad Sci       Date:  1995-09-29       Impact factor: 5.691

3.  Evidence for the overexpression of the VH4-34 (VH4.21) Ig gene segment in the normal adult human peripheral blood B cell repertoire.

Authors:  P Kraj; D F Friedman; F Stevenson; L E Silberstein
Journal:  J Immunol       Date:  1995-06-15       Impact factor: 5.422

Review 4.  The human immunoglobulin VH repertoire.

Authors:  G P Cook; I M Tomlinson
Journal:  Immunol Today       Date:  1995-05

5.  Susceptibility to multiple sclerosis and the immunoglobulin heavy chain variable region.

Authors:  N W Wood; S J Sawcer; H F Kellar-Wood; P Holmans; D Clayton; N Robertson; D A Compston
Journal:  J Neurol       Date:  1995-10       Impact factor: 4.849

6.  The immunoglobulin heavy-chain variable region in insulin-dependent diabetes mellitus: affected-sib-pair analysis and association studies.

Authors:  R Veijola; M Knip; R Puukka; H Reijonen; D W Cox; J Ilonen
Journal:  Am J Hum Genet       Date:  1996-08       Impact factor: 11.025

7.  A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1.

Authors:  T Muster; F Steindl; M Purtscher; A Trkola; A Klima; G Himmler; F Rüker; H Katinger
Journal:  J Virol       Date:  1993-11       Impact factor: 5.103

8.  A broadly neutralizing human monoclonal antibody against gp41 of human immunodeficiency virus type 1.

Authors:  M Purtscher; A Trkola; G Gruber; A Buchacher; R Predl; F Steindl; C Tauer; R Berger; N Barrett; A Jungbauer
Journal:  AIDS Res Hum Retroviruses       Date:  1994-12       Impact factor: 2.205

9.  Monozygotic rheumatoid arthritis twin pairs express similar levels of conserved immunoglobulin V gene in polyclonal rheumatoid factors irrespective of disease status.

Authors:  J Vencovsky; R A Mageed; W E Ollier; R N Maini
Journal:  Scand J Immunol       Date:  1995-07       Impact factor: 3.487

10.  Inter- and intraclonal diversity in the antibody response to influenza hemagglutinin.

Authors:  S H Clarke; K Huppi; D Ruezinsky; L Staudt; W Gerhard; M Weigert
Journal:  J Exp Med       Date:  1985-04-01       Impact factor: 14.307

View more
  42 in total

Review 1.  Broadly neutralizing antibodies and the search for an HIV-1 vaccine: the end of the beginning.

Authors:  Peter D Kwong; John R Mascola; Gary J Nabel
Journal:  Nat Rev Immunol       Date:  2013-09       Impact factor: 53.106

Review 2.  Minding the gap: The impact of B-cell tolerance on the microbial antibody repertoire.

Authors:  Joel Finney; Akiko Watanabe; Garnett Kelsoe; Masayuki Kuraoka
Journal:  Immunol Rev       Date:  2019-09-27       Impact factor: 12.988

3.  A Bivalent, Chimeric Rabies Virus Expressing Simian Immunodeficiency Virus Envelope Induces Multifunctional Antibody Responses.

Authors:  Amber Dunkel; Shixue Shen; Celia C LaBranche; David Montefiori; James P McGettigan
Journal:  AIDS Res Hum Retroviruses       Date:  2015-05-05       Impact factor: 2.205

4.  Preventive and therapeutic applications of neutralizing antibodies to Human Immunodeficiency Virus Type 1 (HIV-1).

Authors:  Rajesh Ringe; Jayanta Bhattacharya
Journal:  Ther Adv Vaccines       Date:  2013-07

5.  Potent and broad HIV-neutralizing antibodies in memory B cells and plasma.

Authors:  LaTonya D Williams; Gilad Ofek; Sebastian Schätzle; Jonathan R McDaniel; Xiaozhi Lu; Nathan I Nicely; Liming Wu; Caleb S Lougheed; Todd Bradley; Mark K Louder; Krisha McKee; Robert T Bailer; Sijy O'Dell; Ivelin S Georgiev; Michael S Seaman; Robert J Parks; Dawn J Marshall; Kara Anasti; Guang Yang; Xiaoyan Nie; Nancy L Tumba; Kevin Wiehe; Kshitij Wagh; Bette Korber; Thomas B Kepler; S Munir Alam; Lynn Morris; Gift Kamanga; Myron S Cohen; Mattia Bonsignori; Shi-Mao Xia; David C Montefiori; Garnett Kelsoe; Feng Gao; John R Mascola; M Anthony Moody; Kevin O Saunders; Hua-Xin Liao; Georgia D Tomaras; George Georgiou; Barton F Haynes
Journal:  Sci Immunol       Date:  2017-01-27

6.  2G12-expressing B cell lines may aid in HIV carbohydrate vaccine design strategies.

Authors:  Katie J Doores; Michael Huber; Khoa M Le; Sheng-Kai Wang; Colleen Doyle-Cooper; Anthony Cooper; Ralph Pantophlet; Chi-Huey Wong; David Nemazee; Dennis R Burton
Journal:  J Virol       Date:  2012-12-05       Impact factor: 5.103

7.  Anti-HIV B Cell lines as candidate vaccine biosensors.

Authors:  Takayuki Ota; Colleen Doyle-Cooper; Anthony B Cooper; Michael Huber; Emilia Falkowska; Katherine J Doores; Lars Hangartner; Khoa Le; Devin Sok; Joseph Jardine; Jeffrey Lifson; Xueling Wu; John R Mascola; Pascal Poignard; James M Binley; Bimal K Chakrabarti; William R Schief; Richard T Wyatt; Dennis R Burton; David Nemazee
Journal:  J Immunol       Date:  2012-10-12       Impact factor: 5.422

8.  Vaccine induction of antibodies against a structurally heterogeneous site of immune pressure within HIV-1 envelope protein variable regions 1 and 2.

Authors:  Hua-Xin Liao; Mattia Bonsignori; S Munir Alam; Jason S McLellan; Georgia D Tomaras; M Anthony Moody; Daniel M Kozink; Kwan-Ki Hwang; Xi Chen; Chun-Yen Tsao; Pinghuang Liu; Xiaozhi Lu; Robert J Parks; David C Montefiori; Guido Ferrari; Justin Pollara; Mangala Rao; Kristina K Peachman; Sampa Santra; Norman L Letvin; Nicos Karasavvas; Zhi-Yong Yang; Kaifan Dai; Marie Pancera; Jason Gorman; Kevin Wiehe; Nathan I Nicely; Supachai Rerks-Ngarm; Sorachai Nitayaphan; Jaranit Kaewkungwal; Punnee Pitisuttithum; James Tartaglia; Faruk Sinangil; Jerome H Kim; Nelson L Michael; Thomas B Kepler; Peter D Kwong; John R Mascola; Gary J Nabel; Abraham Pinter; Susan Zolla-Pazner; Barton F Haynes
Journal:  Immunity       Date:  2013-01-11       Impact factor: 31.745

Review 9.  HIV-1 neutralizing antibodies: understanding nature's pathways.

Authors:  John R Mascola; Barton F Haynes
Journal:  Immunol Rev       Date:  2013-07       Impact factor: 12.988

10.  Initiation of immune tolerance-controlled HIV gp41 neutralizing B cell lineages.

Authors:  Ruijun Zhang; Laurent Verkoczy; Kevin Wiehe; S Munir Alam; Nathan I Nicely; Sampa Santra; Todd Bradley; Charles W Pemble; Jinsong Zhang; Feng Gao; David C Montefiori; Hilary Bouton-Verville; Garnett Kelsoe; Kevin Larimore; Phillip D Greenberg; Robert Parks; Andrew Foulger; Jessica N Peel; Kan Luo; Xiaozhi Lu; Ashley M Trama; Nathan Vandergrift; Georgia D Tomaras; Thomas B Kepler; M Anthony Moody; Hua-Xin Liao; Barton F Haynes
Journal:  Sci Transl Med       Date:  2016-04-27       Impact factor: 17.956

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.